ArticleAsian Pacific journal of cancer prevention : APJCP2026
Improved Overall Survival Due to Reduced Waiting Time in Nasopharyngeal Cancer Patients Treated with Chemoradiotherapy in Yogyakarta, Indonesia.
Article in Asian Pacific journal of cancer prevention : APJCP, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn Indonesia, nasopharyngeal carcinoma (NPC) is highly prevalent and is one of the leading causes of cancer-related mortality. Lower overall survival (OS), compared to neighboring countries, is associated with a prolonged waiting time (WT) and overall radiotherapy (RT) treatment time (OTT). In 2018, the RT department of the Dr. Sardjito Hospital in Yogyakarta, Indonesia, increased the number of treatment machines and clinical staff. This may have led to an improvements in WT and OTT. Therefore, we analyzed a recent cohort of NPC patients to evaluate the outcomes in light of these changes. MATERIALS AND
methodsA retrospective cohort of 229 NPC patients underwent chemoradiotherapy with curative intent between January 2018 and December 2021. The majority had locally advanced NPC. The turning point was in 2018, marking a pivotal year. Consequently, the years 2019-2021 were compared with 2018. Endpoints included WT, OTT, OS, as well as locoregional control (LRC) and disease-free survival (DFS).
resultsThe mean follow-up time was 16.9 months. For all patients, the median WT and OTT were 110 days and 50 days. Comparing 2018 with 2019-2021, the WT differed significantly with 190 versus 97 days (p<0.001) while the OTT, 53 versus 50 days, was borderline different (p=0.049). The 2-year OS significantly improved from 42.6% in 2018 to 60.5% among patients treated between 2019-2021 (p=0.042).
conclusionIn conclusion, this study analyzed the impact of WT and OTT on outcomes for NPC patients undergoing chemoradiotherapy at Dr. Sardjito Hospital. A significant decrease in WT of 97 days was observed when compared to 2018. However, the limited availability of advanced imaging likely resulted in an underestimation of distant metastases, leading to a 2-yr OS of 60.5%. Better staging methods, as well as improved awareness of NPC, are crucial for better treatment decisions and improving future patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.